<DOC>
	<DOCNO>NCT01193621</DOCNO>
	<brief_summary>In present study , investigator establish clinical trial technology early evaluation drug characteristic term pharmacokinetics pharmacodynamics haloperidol model drug , use positron emission tomography .</brief_summary>
	<brief_title>Early Clinical Evaluation Pharmacokinetics Mechanism Based Pharmacodynamics Haloperidol Using Positron Emission Tomography Healthy Volunteers</brief_title>
	<detailed_description>1 . Study Design This study consist two part . One `` biodistribution study haloperidol '' 12 subject , `` receptor occupancy study haloperidol '' 12 subject . In biodistribution study , 18F-haloperidol ( 10 mCi ) inject intravenously two time 12 subject ( cross-over design ) . Whole body PET conduct first haloperidol injection local brain PET 2nd haloperidol injection 7 day washout period . 1.1 D2-receptor occupancy study Group Doses No . subject 1 0.5 mg 4 2 1 mg 4 3 3 mg 4 2 . Measurement 2.1 The D2 receptor Occupancy haloperidol . 3 . Test schedule 3.1 Biodistribution study - Whole body PET ( day 1 ) - Brain local PET ( day 8 ) 3.2 Receptor occupancy study - Baseline PET drug administration ( day 1 0h ) , 6h ( day 1 6h ) , 24h ( day 2 0h ) , first haloperidol administration ( day 1 0h ) , 24 h ( day 8 ) , 72 h ( day 10 ) , 168 h ( day 14 ) last dosing haloperidol ( day 7 0h ) . - Drug administration day 1 day 7 every 24 hour PK blood sampling ( 6 ml , ) prior first haloperidol administration ( day 1 0h ) 6h ( 1 day 6h ) , 24h ( 2 day 0h ) , 48 h ( 3 day 0h ) , 96 h ( 5 day 0h ) , 144 h ( 7 day 0h ) , 0.5 , 1 , 2 , 4 , 6 , 8 , 12 , 24 h ( 8day 0h ) , 48h ( 9day 0h ) , 72h ( 10 day 0h ) take last oral dose haloperidol 4 . Analytic Methods 4.1 Pharmacokinetics : Noncompartmental Analysis Using Winnonlin Compartment model use NONMEM VII 4.2 Pharmacodynamics brain : Emax linear model use NONMEM VII</detailed_description>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Overtly healthy male determine medical history physical examination Age 19 45 year Weight ≥ 45 kg within ± 20 % IBW Clinical laboratory test result within normal reference range National Cancer Center , Hospital result minor deviation judge clinically significant investigator Normal blood pressure heart rate ( supine standing ) determine investigator Are reliable willing make available duration study , abide study restriction Have give write informed consent History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , neurological disorder capable alter absorption , metabolism elimination drug , constitute risk factor take study medication An episode febrile disease infectious disease within past 2 week Evidence significant active hematologic disease and/or blood donation last 2 month Evidence significant active neuropsychiatric disease Regular use drug abuse History drug hypersensitivity clinically significant allergic reaction origin Participation study involve administration investigational compound within past 30 day Have regular alcohol intake great 21 units/week subject unwilling stop alcohol duration study period Intend use concomitant drug therapy , include non prescription medication regular basis apart vitamin/mineral supplement Smoking history recent 3 month Use medication within 7 day prior study . If situation arise inclusion otherwise suitable volunteer may discretion investigator</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>early evaluation</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Biodistribution</keyword>
	<keyword>D2-receptor occupancy</keyword>
</DOC>